Literature DB >> 15880475

Blood levels of free-PSA but not complex-PSA significantly correlates to prostate release of PSA in semen in young men, while blood levels of complex-PSA, but not free-PSA increase with age.

Charlotta Sävblom1, Johan Malm, Aleksander Giwercman, Jan-Ake Nilsson, Göran Berglund, Hans Lilja.   

Abstract

BACKGROUND: The proportion of free- and complex-prostate specific antigen (PSA) in serum is used for differentiating between benign and malignant prostate disease. To further understand the physiological relationship between PSA in seminal plasma and blood, we have analyzed free-PSA (fPSA) and complex-PSA (cPSA) in blood and PSA in seminal plasma in young healthy men. We also compared age-related changes of PSA-forms in blood from young versus older men.
METHODS: Total-PSA (tPSA), fPSA, and cPSA were measured in (i) blood and semen from 289 male conscripts (mean age 18.1 years) and in (ii) blood from a representative population of 1,389 men (mean age 46.5 years) without diagnosis of prostate cancer (PCa) during long-term follow-up.
RESULTS: fPSA in serum (r = 0.40, P < 0.0001) but not cPSA (r = 0.09, P = 0.11), correlates to PSA in seminal fluid. fPSA levels in blood in young (geometric mean: 0.20 ng/ml) versus middle-aged men (geometric mean: 0.18 ng/ml) was not different (P = 0.06), whereas cPSA in middle-aged men (geometric mean: 0.38 ng/ml) was higher (P < 0.0001) than in young men (geometric mean: 0.28 ng/ml).
CONCLUSIONS: fPSA in blood, but not cPSA, is associated to PSA in semen ( approximately 17% co-variation). In blood cPSA, but not fPSA, increase with age in healthy men, which may reflect an increasing incidence of prostate disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15880475     DOI: 10.1002/pros.20254

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  10 in total

1.  Radiolabeled antibodies in prostate cancer: a case study showing the effect of host immunity on antibody bio-distribution.

Authors:  Oskar Vilhelmsson-Timmermand; Elmer Santos; Daniel L J Thorek; Susan Evans-Axelsson; Anders Bjartell; Hans Lilja; Steven M Larson; Sven-Erik Strand; Thuy A Tran; David Ulmert
Journal:  Nucl Med Biol       Date:  2014-12-23       Impact factor: 2.408

Review 2.  Prostate-specific kallikrein-related peptidases and their relation to prostate cancer biology and detection. Established relevance and emerging roles.

Authors:  Daniel L J Thorek; Michael J Evans; Sigrid V Carlsson; David Ulmert; Hans Lilja
Journal:  Thromb Haemost       Date:  2013-08-01       Impact factor: 5.249

Review 3.  [Minimally invasive treatment of benign prostatic hyperplasia].

Authors:  G Magistro; C G Stief; C Gratzke
Journal:  Urologe A       Date:  2016-11       Impact factor: 0.639

Review 4.  New intraprostatic injectables and prostatic urethral lift for male LUTS.

Authors:  Giuseppe Magistro; Christian G Stief; Christian Gratzke
Journal:  Nat Rev Urol       Date:  2015-07-21       Impact factor: 14.432

5.  Polymorphisms at the Microseminoprotein-beta locus associated with physiologic variation in beta-microseminoprotein and prostate-specific antigen levels.

Authors:  Xing Xu; Camilla Valtonen-André; Charlotta Sävblom; Christer Halldén; Hans Lilja; Robert J Klein
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-08       Impact factor: 4.254

6.  Genetic variation in KLK2 and KLK3 is associated with concentrations of hK2 and PSA in serum and seminal plasma in young men.

Authors:  Charlotta Sävblom; Christer Halldén; Angel M Cronin; Torbjörn Säll; Caroline Savage; Emily A Vertosick; Robert J Klein; Aleksander Giwercman; Hans Lilja
Journal:  Clin Chem       Date:  2013-11-22       Impact factor: 8.327

7.  Evaluation of molecular forms of prostate-specific antigen and human kallikrein 2 in predicting biochemical failure after radical prostatectomy.

Authors:  Sven Wenske; Ruslan Korets; Angel M Cronin; Andrew J Vickers; Martin Fleisher; Howard I Scher; Kim Pettersson; Bertrand Guillonneau; Peter T Scardino; James A Eastham; Hans Lilja
Journal:  Int J Cancer       Date:  2009-02-01       Impact factor: 7.396

8.  Novel biomarkers for the detection of prostate cancer.

Authors:  Niels Asger Jakobsen; Freddie Charles Hamdy; Richard John Bryant
Journal:  J Clin Urol       Date:  2016-12-01

9.  Improving the detection rate of prostate cancer in the gray zone of PI-RADS v2 and serum tPSA by using prostate-specific antigen-age volume.

Authors:  Yuan-Fei Lu; Qian Zhang; Hai-Yan Chen; Jie-Yu Chen; Yao Pan; Cong-Cong Xu; Jian-Xia Xu; Ri-Sheng Yu
Journal:  Medicine (Baltimore)       Date:  2019-06       Impact factor: 1.817

10.  Full-length antibodies versus single-chain antibody fragments for a selective impedimetric lectin-based glycoprofiling of prostate specific antigen.

Authors:  Stefan Belicky; Pavel Damborsky; Julia Zapatero-Rodríguez; Richard O'Kennedy; Jan Tkac
Journal:  Electrochim Acta       Date:  2017-08-20       Impact factor: 6.901

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.